Two of them do it better: Novel serum biomarkers improve autoimmune hepatitis diagnosis

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Mazzara, Saveria ^a   Sinisi, Antonia ^a   Cardaci, Angela ^a   Rossi, Riccardo Lorenzo ^a   Muratori, Luigi ^c   Abrignani, Sergio ^a,b   Bombaci, Mauro ^a  

^a Istituto Nazionale di Genetica Molecolare   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; BIOLOGICAL MARKER; CHONDROADHERIN PRECURSOR; PROTEIN UNQ9419; UNCLASSIFIED DRUG; AUTOANTIBODY; CHONDROADHERIN; SCLEROPROTEIN;

ADULT; ANTIBODY DETECTION; AREA UNDER THE CURVE; ARTICLE; AUTOIMMUNE HEPATITIS; BIOINFORMATICS; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; IMMUNOFLUORESCENCE TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREDICTION; PROTEIN ANALYSIS; PROTEIN MICROARRAY; PROTEIN PROTEIN INTERACTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; HEPATITIS, AUTOIMMUNE; IMMUNOBLOTTING; IMMUNOLOGY; PROCEDURES; PROGNOSIS;

ADULT; AUTOANTIBODIES; AUTOANTIGENS; BIOMARKERS; CASE-CONTROL STUDIES; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOBLOTTING; MALE; MIDDLE AGED; PROGNOSIS; PROTEIN ARRAY ANALYSIS;

EID: 84945977215     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0137927     Document Type: Article

References (52)

1. Bogdanos DP, Invernizzi P, Mackay IR, Vergani D. Autoimmune liver serology: current diagnostic and clinical challenges. World journal of gastroenterology: WJG. 2008; 14(21):3374-87.
2. Vergani D, Alvarez F, Bianchi FB, Cancado EL, Mackay IR, Manns MP, et al. Liver autoimmune serology: A consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. Journal of hepatology. 2004; 41(4):677-83.
3. Hennes EM, Zeniya M, Czaja AJ, Pares A, Dalekos GN, Krawitt EL, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008; 48(1):169-76. doi: 10.1002/hep.22322
4. Zachou K, Rigopoulou E, Dalekos GN. Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease. Journal of autoimmune diseases. 2004; 1(1):2. doi: 10.1186/1740-2557-1-2
5. MacBeath G. Protein microarrays and proteomics. Nature genetics. 2002; 32 Suppl:526-32.
6. Saeed AI, Bhagabati NK, Braisted JC, Liang W, Sharov V, Howe EA, et al. TM4 microarray software suite. Methods Enzymol. 2006; 411:134-93.
7. Jeong JS, Jiang L, Albino E, Marrero J, Rho HS, Hu J, et al. Rapid identification of monospecific monoclonal antibodies using a human proteome microarray. Mol Cell Proteomics. 2012; 11(6):O111 016253. doi: 10.1074/mcp.O111.016253
8. Song Q, Liu G, Hu S, Zhang Y, Tao Y, Han Y, et al. Novel autoimmune hepatitis-specific autoantigens identified using protein microarray technology. Journal of proteome research. 2010; 9(1):30-9. doi: 10. 1021/pr900131e
9. Wu L, Song G. Identification of new autoimmune hepatitis-specific autoantigens by using protein microarray technology. Methods in molecular biology. 2012; 909:227-39. doi: 10.1007/978-1-61779-959-4-15.
10. Inza I, Calvo B, Armananzas R, Bengoetxea E, Larranaga P, Lozano JA. Machine learning: An indispensable tool in bioinformatics. Methods Mol Biol. 2010; 593:25-48. doi: 10.1007/978-1-60327-194-3-2
11. Christin C, Hoefsloot HC, Smilde AK, Hoekman B, Suits F, Bischoff R, et al. A critical assessment of feature selection methods for biomarker discovery in clinical proteomics. Mol Cell Proteomics. 2013; 12 (1):263-76. doi: 10.1074/mcp.M112.022566
12. Jain AK DR, Mao J Statistical pattern recognition: A review. IEEE Trans Pattern Analysis Machine Intelligence. 2000; 22:4-37.
13. Hastie T, Tibshirani R, Friedmann J. The elements of statistical learning. Data mining, inference and prediction. Springer Series ed. Statistics SSi, editor: Springer; 2009.
14. Baumgartner C, Osl M, Netzer M, Baumgartner D. Bionformatic-driven search for metabolic biomarker in disease. Journal of clinical bioinformatics. 2011; 1(2):1-10.
15. Barker M, Rayens W. Partial least squares for discrimination. J Chemom. 2003; 17:166-73.
16. Wold S, Sjöström M, Eriksson L. PLS-regression: A basic tool of chemomterics. Chem Intell Lab System. 2001; 58:109-30.
17. Hilario M, Kalousis A. Approaches to dimensionality reduction in proteomic biomarker studies. Brief Bioinform. 2008; 9(2):102-18. doi: 10.1093/bib/bbn005
18. Eriksson L JE, Kettaneh-Wold N, Trygg J, Wikström C, Wold S. Multi-And megavariate data analysis. Basic Principles and Applications2006
19. Perez-Enciso M, Tenenhaus M. Prediction of clinical outcome with microarray data: A partial least squares discriminant analysis (PLS-DA) approach. Hum Genet. 2003; 112(5-6):581-92.
20. Nguyen DV, Rocke DM. Multi-class cancer classification via partial least squares with gene expression profiles. Bioinformatics. 2002; 18(9):1216-26.
21. Nguyen DV, Rocke DM. Tumor classification by partial least squares using microarray gene expression data. Bioinformatics. 2002; 18(1):39-50.
22. Fernandez-Perez L, Novoa J, Stahlberg N, Santana-Farre R, Boronat M, Marrero D, et al. The effect of in vivo growth hormone treatment on blood gene expression in adults with growth hormone deficiency reveals potential biomarkers to monitor growth hormone therapy. Clin Endocrinol (Oxf). 2010; 72 (6):800-6.
23. Rosenberg LH, Franzén B, Auer G, Lehtiö J, Forshed J. Multivariate meta-Analysis of proteomics data from human prostate and colon tumours. BMC Bioinformatics. 2010; 11:468. doi: 10.1186/1471-2105-11-468
24. Hyung SW, Lee MY, Yu JH, Shin B, Jung HJ, Park JM, et al. A serum protein profile predictive of the resistance to neoadjuvant chemotherapy in advanced breast cancers. Mol Cell Proteomics. 2011; 10 (10):M111 011023. doi: 10.1074/mcp.M111.011023
25. Hu CJ, Song G, Huang W, Liu GZ, Deng CW, Zeng HP, et al. Identification of new autoantigens for primary biliary cirrhosis using human proteome microarrays. Mol Cell Proteomics. 2012; 11(9):669-80. doi: 10.1074/mcp.M111.015529
26. Chen J, Zhang X, Cao R, Lu X, Zhao S, Fekete A, et al. Serum 27-nor-5beta-cholestane-3,7,12,24,25 pentol glucuronide discovered by metabolomics as potential diagnostic biomarker for epithelium ovarian cancer. J Proteome Res. 2011; 10(5):2625-32. doi: 10.1021/pr200173q
27. Zheng P, Wang Y, Chen L, Yang D, Meng H, Zhou D, et al. Identification and validation of urinary metabolite biomarkers for major depressive disorder. Mol Cell Proteomics. 2013; 12(1):207-14. doi: 10.1074/mcp.M112.021816
28. Pacchiarotta T, Hensbergen PJ, Wuhrer M, van Nieuwkoop C, Nevedomskaya E, Derks RJ, et al. Fibrinogen alpha chain O-glycopeptides as possible markers of urinary tract infection. Journal of proteomics. 2012; 75(3):1067-73. doi: 10.1016/j.jprot.2011.10.021
29. Ayoglu B, Haggmark A, Khademi M, Olsson T, Uhlen M, Schwenk JM, et al. Autoantibody profiling in multiple sclerosis using arrays of human protein fragments. Mol Cell Proteomics. 2013; 12(9):2657-72. doi: 10.1074/mcp.M112.026757
30. Mazzara S, Cerutti S, Iannaccone S, Conti A, Olivieri S, Alessio M, et al. pplication of Multivariate Data Analysis for the Classification of Two Dimensional Gel Images in Neuroproteomics. J Proteomics Bioinform. 2011;(4: ):16-21.
31. Zingaretti C, Arigo M, Cardaci A, Moro M, Crosti M, Sinisi A, et al. Identification of new autoantigens by protein array indicates a role for IL4 neutralization in autoimmune hepatitis. Mol Cell Proteomics. 2012; 11(12):1885-97. doi: 10.1074/mcp.M112.018713
32. Hu CJ, Zhang FC, Li YZ, Zhang X. Primary biliary cirrhosis: what do autoantibodies tell us? World journal of gastroenterology: WJG. 16(29):3616-29.
33. Bombaci M, Grifantini R, Mora M, Reguzzi V, Petracca R, Meoni E, et al. Protein array profiling of tic patient sera reveals a broad range and enhanced immune response against Group A Streptococcus antigens. PLoS One. 2009; 4(7):e6332. doi: 10.1371/journal.pone.0006332
34. Duda R, Hart P, Stork D. Pattern Classification and Scene Analysis2001.
35. Zhang X, Lu X, Shi Q, Xu XQ, Leung HC, Harris LN, et al. Recursive SVM feature selection and sample classification for mass-spectrometry and microarray data. BMC Bioinformatics. 2006; 7:197.
36. Tenenhaus M. La Regression PLS: Theorie et pratique. Editions TECHNIP ed. Paris1998.
37. R Development Core Team. R: A Language and Environment for Statistical Computing 2011.
38. Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, Minguez P, et al. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic acids research. 2011; 39(Database issue):D561-8. doi: 10.1093/nar/gkq973
39. Joliffe IT. Principal Component Analysis Springer ed2002.
40. Poynard T, Halfon P, CAstera L, Munteanu M, Imbert-Bismut F, Ratziu V, et al. Standardization of ROC curve for diagnostic of fibrosis Stages. Clin Chem. 2007; 53:1615-22.
41. Grifantini R, Pagani M, Pierleoni A, Grandi A, Parri M, Campagnoli S, et al. A novel polyclonal antibody library for expression profiling of poorly characterized, membrane and secreted human proteins. Journal of proteomics. 75(2):532-47. doi: 10.1016/j.jprot.2011.08.018
42. Moreth K, Iozzo RV, Schaefer L. Small leucine-rich proteoglycans orchestrate receptor crosstalk during inflammation. Cell cycle. 2012; 11(11):2084-91. doi: 10.4161/cc.20316
43. Iozzo RV, Schaefer L. Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans. The FEBS journal. 2010; 277(19):3864-75. doi: 10.1111/j.1742-4658.2010.07797.x
44. Horiguchi K, Syaidah R, Fujiwara K, Tsukada T, Ramadhani D, Jindatip D, et al. Expression of small leucine-rich proteoglycans in rat anterior pituitary gland. Cell and tissue research. 2013; 351 (1):207-12. doi: 10.1007/s00441-012-1513-6.
45. Yamaguchi Y, Mann DM, Ruoslahti E. Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature. 1990; 346(6281):281-4.
46. Baghy K, Iozzo RV, Kovalszky I. Decorin-TGFbeta axis in hepatic fibrosis and cirrhosis. The journal of histochemistry and cytochemistry: official journal of the Histochemistry Society. 2012; 60(4):262-8. doi: 10.1369/0022155412438104
47. Shi YF, Zhang Q, Cheung PY, Shi L, Fong CC, Zhang Y, et al. Effects of rhDecorin on TGF-beta1 induced human hepatic stellate cells LX-2 activation. Biochimica et biophysica acta. 2006; 1760 (11):1587-95.
48. Zhang Z, Li XJ, Liu Y, Zhang X, Li YY, Xu WS. Recombinant human decorin inhibits cell proliferation and downregulates TGF-beta1 production in hypertrophic scar fibroblasts. Burns: journal of the International Society for Burn Injuries. 2007; 33(5):634-41.
49. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: A mechanism for regulating pulmonary inflammation and fibrosis. Cell. 1999; 96(3):319-28.
50. Carbonell WS, DeLay M, Jahangiri A, Park CC, Aghi MK. beta1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma. Cancer research. 2013; 73(10):3145-54. doi: 10.1158/0008-5472.CAN-13-0011.
51. Makol A, Watt KD, Chowdhary VR. Autoimmune hepatitis: A review of current diagnosis and treatment. Hepatitis research and treatment. 2011; 2011:390916. doi: 10.1155/2011/390916
52. Muratori P, Granito A, Pappas G, Pendino GM, Quarneti C, Cicola R, et al. The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome. Am J Gastroenterol. 2009; 104 (6):1420-5. doi: 10.1038/ajg.2009.126